Which of your patients could benefit from JYSELECA?
Patients with UC in the SELECTION study had varying levels of treatment experience
Biologic-Naïve patients in the SELECTION clinical trial (n = 659)1
Concomitant medications at baseline
Reference: 1. Feagan BG, Danese S, Loftus EV Jr, et al. Lancet 2021;397:2372–2384.
INDICATIONS: JYSELECA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
Jyseleca, Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
Date of preparation March 2022
You are about to leave this website and will be redirected to an external website. We are not responsible of that external website’s content. By continuing, you confirm that you have taken note of this.